Well Referenced

Category: Cancer & Oncology Support

Supportive and adjunctive therapies for cancer prevention and treatment.

Modulating tumor reactive stroma by extracorporeal shock waves to control prostate cancer progression

This in vitro study investigated the effects of extracorporeal shock waves (ESWs) on carcinoma-associated fibroblasts (CAFs) derived from high-risk prostate cancer patients. ESW treatment at specified energy levels reduced the expression of stromal activation markers α-smooth muscle actin (α-SMA) and type I collagen (COL1) in CAFs. Conditioned media from ESW-treated

Read More »
June 26, 2025 No Comments

The Effect of Vitamin C (Ascorbic Acid) in the Treatment of Patients with Cancer: A Systematic Review

This 2019 systematic review assessed the efficacy and safety of vitamin C supplementation in cancer treatment. Nineteen trials were included, with only four employing randomization. The studies varied widely in design, patient populations, and intervention protocols. Overall, the evidence did not demonstrate a clinically significant benefit of vitamin C on

Read More »
June 26, 2025 No Comments

Vitamin C as a Modulator of the Response to Cancer Therapy

This 2019 review examines the role of vitamin C (ascorbic acid) as an adjunct in cancer therapy. At pharmacological concentrations, vitamin C exhibits pro-oxidant properties, generating reactive oxygen species that selectively induce cytotoxicity in cancer cells. It also modulates epigenetic mechanisms by influencing DNA and histone demethylation, affecting gene expression

Read More »
June 26, 2025 No Comments

Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study

This phase 1, open-label, dose-expansion study evaluated the safety and preliminary efficacy of trastuzumab deruxtecan (DS-8201a) in 115 patients with advanced HER2-positive breast cancer who had previously received trastuzumab emtansine. Patients received intravenous doses of 5.4 mg/kg or 6.4 mg/kg every three weeks. The confirmed objective response rate was 59.5%

Read More »
June 26, 2025 No Comments

Observations on the Doubling Time of Prostate Cancer: The Use of Serial Prostate-Specific Antigen in Patients with Untreated Disease as a Measure of Increasing Cancer Volume

This 1993 study evaluated PSA doubling times (PSADT) in 43 patients with untreated prostate cancer over an average of 30 months. The findings demonstrated that PSA levels increased in a log-linear (exponential) fashion, with doubling times varying significantly based on tumor stage and grade. Patients with higher-stage and higher-grade tumors

Read More »
June 26, 2025 No Comments

Anti-cancer effect of pharmacologic ascorbate and its interaction with supplementary parenteral glutathione in preclinical cancer models

This 2011 study by Chen et al. investigates the anti-cancer effects of high-dose intravenous ascorbic acid (AA) and its interaction with intravenous glutathione (GSH) in preclinical cancer models. The research demonstrates that pharmacologic concentrations of AA induce cytotoxicity in various cancer cell lines through the generation of hydrogen peroxide (H₂O₂),

Read More »
June 26, 2025 No Comments

Assessment of Breast Cancer Mortality Trends Associated With Mammographic Screening and Adjuvant Therapy From 1986 to 2013 in the State of Victoria, Australia

This 2020 population-based cohort study evaluated breast cancer mortality trends in Victoria, Australia, over a 27-year period, analyzing the relative contributions of mammographic screening and adjuvant therapy. Using data from the Victorian Cancer Registry and BreastScreen Victoria, the researchers applied age-period-cohort modeling to isolate the effects of each intervention. Results

Read More »
June 26, 2025 No Comments

β-D-glucan inhibits endocrine-resistant breast cancer cell proliferation and alters gene expression

This 2014 study examined the anticancer effects of β-D-glucan on various breast cancer cell lines, particularly those resistant to endocrine therapy. The compound significantly inhibited cell proliferation in endocrine-resistant lines (LCC9 and LY2) at low micromolar concentrations, while having limited effects on normal breast epithelial cells and triple-negative breast cancer

Read More »
June 26, 2025 No Comments